<DOC>
	<DOCNO>NCT02137772</DOCNO>
	<brief_summary>The study evaluate efficacy safety MK-8228 prevention clinically-significant CMV infection adult , CMV-seropositive recipient allogeneic hematopoietic stem cell transplant . The hypothesis test MK-8228 superior placebo prevention clinically-significant CMV infection 24 week transplant .</brief_summary>
	<brief_title>MK-8228 ( Letermovir ) Versus Placebo Prevention Clinically-Significant Cytomegalovirus ( CMV ) Infection Adult , CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients ( MK-8228-001 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Has document seropositivity CMV within 1 year hematopoietic stem cell transplant ( HSCT ) Receiving first allogeneic HSCT ( bone marrow , peripheral blood stem cell , cord blood transplant ) Female male participant reproductive potential , , reproductive potential , agree true abstinence use ( partner use ) 2 acceptable method birth control time consent 90 day last dose study drug Able read , understand , complete questionnaire diary Received previous allogeneic HSCT ( previous autologous HSCT acceptable ) History CMV endorgan disease within 6 month randomization Has evidence CMV viremia ( test ) time either signing Informed Consent Form HSCT procedure , whichever earlier , time randomization . Received follow within 7 day screen plan receive study : ganciclovir , valganciclovir , foscarnet , acyclovir , valacyclovir , famciclovir Received follow within 30 day screen plan receive study : cidofovir , CMV hyperimmune globulin , investigational CMV antiviral agent biological therapy Has suspect know hypersensitivity ingredient MK8228 ( letermovir ) formulation Has severe hepatic insufficiency within 5 day randomization Has endstage renal impairment Has uncontrolled infection day randomization Requires mechanical ventilation hemodynamically unstable time randomization Has document positive result human immunodeficiency virus ( HIV ) antibody , hepatitis C virus ( HCV ) antibody detectable HCV ribonucleic acid , hepatitis B surface antigen ( HBsAg ) within 90 day randomization Has active solid tumor malignancy exception localize basal cell squamous cell skin cancer condition treatment ( example , lymphoma ) Is pregnant expect conceive , breastfeeding , plan breastfeed time consent 90 day last dose study drug Is expect donate egg sperm time consent 90 day last dose study drug Has participate study unapproved investigational compound ( monoclonal antibody except ) device within 28 day first dose study drug Has previously participate MK8228 ( letermovir ) study Has , , planning ( study ) participate study involve administration CMV vaccine another CMV investigational agent Is user recreational illicit drug recent history ( &lt; =1 year ) drug alcohol abuse dependence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>